RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
Amylyx Pharmaceuticals, Inc. today announced that several abstracts detailing data on AMX0035 and the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of...
Source: marketscreener.com